Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura

American Journal of Hematology

Volumn 90, Issue 1, 2015, Pages E22-

  Raval, Jay S ^a,b,d   Padmanabhan, Anand ^a,b,e,f   Kremer Hovinga, Johanna A ^c   Kiss, Joseph E ^a,b  

^a INSTITUTE FOR TRANSFUSION MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ADULT; CASE REPORT; CHRONIC KIDNEY FAILURE; EXON; FAMILY HISTORY; FEMALE; GENE SEQUENCE; GENETIC DISORDER; HUMAN; IMMUNOMODULATION; LETTER; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; MUTATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

ADAM PROTEINS; ADULT; FEMALE; HUMANS; MUTATION; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 84919625380     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23851     Document Type: Letter

References (5)

1. Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978;298:1350-1352.
2. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-494.
3. Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011;9:283-301.
4. Reese MG. Available at: http://www.fruitfly.org/seq_tools/splice.html>. Accessed on November 23, 2011.
5. Kruse-Jarres R. Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A. Hematology Am Soc Hematol Educ Program 2011;2011:407-412.